What Is Tesamorelin?
Tesamorelin (CAS 218949-48-5) is a synthetic analog of human growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification confers enhanced metabolic stability and resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). Tesamorelin has a molecular weight of 5135.83 Da and is classified within the growth factor / GH-IGF peptide category.
Tesamorelin was developed by Theratechnologies Inc. and has been the subject of extensive clinical and preclinical investigation. It is one of the most well-characterized GHRH analogs in the research literature, with multiple published randomized controlled trials evaluating its effects on body composition, particularly visceral adipose tissue. The compound acts via selective stimulation of the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, triggering pulsatile growth hormone (GH) release that mimics physiological secretion patterns.
For wholesale peptide buyers supplying clinical research sites, academic endocrinology labs, and metabolic research centers, Tesamorelin represents a high-demand compound with robust published data. Access our wholesale peptide program for institutional pricing and bulk availability.
Mechanism of Action
Tesamorelin functions as a selective GHRH receptor agonist. Upon binding to the GHRH receptor, a G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary, Tesamorelin activates the cAMP/PKA signaling cascade. This leads to transcriptional activation of the GH1 gene and subsequent synthesis and secretion of growth hormone into systemic circulation.
The N-terminal trans-3-hexenoic acid modification is critical to Tesamorelin’s pharmacological profile. Native GHRH(1-44) is rapidly cleaved by DPP-IV at the Tyr1-Ala2 bond, yielding inactive GHRH(3-44). The hexenoic acid cap sterically hinders DPP-IV access, substantially extending the peptide’s circulating half-life without altering receptor binding specificity or affinity.
Downstream of GH release, Tesamorelin indirectly stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which mediates many of the anabolic and metabolic effects attributed to the GH axis. Importantly, because Tesamorelin preserves pulsatile GH secretion rather than producing continuous supraphysiological GH levels, it maintains negative feedback integrity at the hypothalamic-pituitary axis. Researchers frequently compare Tesamorelin with other GH secretagogues such as Ipamorelin, CJC-1295, and Hexarelin for mechanistic differentiation studies.
Research Applications
Tesamorelin has one of the most extensive research profiles of any GHRH analog, with applications spanning metabolic, endocrine, and neuroscience research domains:
Visceral Adiposity and Body Composition
The most extensively documented research application for Tesamorelin involves its effects on visceral adipose tissue (VAT). Multiple randomized, placebo-controlled trials have studied Tesamorelin’s capacity to reduce trunk fat accumulation. Researchers have documented significant reductions in VAT as measured by CT imaging, along with improvements in waist circumference and trunk-to-limb fat ratios. These findings are of particular relevance to investigators studying metabolic syndrome, lipodystrophy, and adipose tissue biology.
Growth Hormone Axis Research
As a selective GHRHR agonist, Tesamorelin serves as an important pharmacological tool for studying the GH-IGF-1 axis. Researchers have used it to investigate pulsatile versus continuous GH stimulation, pituitary responsiveness in aging models, and the differential metabolic effects of GH secretagogue classes. It is frequently studied alongside CJC-1295 and Ipamorelin in comparative secretagogue research.
Cognitive and Neurological Research
Emerging research has investigated Tesamorelin’s effects on cognitive function. Studies have examined its influence on hippocampal-dependent memory tasks and brain amyloid-beta levels in preclinical and early-phase clinical models, positioning the compound as relevant to neuroendocrine aging and neurodegeneration research.
Metabolic Biomarker Studies
Researchers have studied Tesamorelin in animal models for its effects on metabolic biomarkers including triglycerides, C-reactive protein (CRP), and adiponectin. These studies explore the downstream metabolic consequences of physiological GH restoration. Related weight management peptides such as AOD-9604 and Cagrilintide are often investigated in parallel.
Institutions requiring bulk supply for multi-site trials or longitudinal studies can access dedicated pricing at the Tesamorelin wholesale page.
Available Formats and Bulk Options
Tesamorelin is available through Wholesale Bulk Peptides in formats designed for diverse research scales:
- 2 mg lyophilized vials — suitable for receptor binding assays, pilot pharmacokinetic studies, and small-scale in vivo experiments
- 5 mg lyophilized vials — optimized for dose-escalation and multi-arm research protocols
- Bulk lyophilized powder — gram-scale quantities available for contract research organizations, clinical trial suppliers, and private-label peptide manufacturers
Custom formulations are available for qualified wholesale accounts. Visit our wholesale program application to request access.
Wholesale Pricing Summary
Tesamorelin wholesale pricing reflects its higher molecular weight and complex synthesis, with volume-tiered discounts for institutional and bulk buyers. For complete pricing information, minimum order quantities, and scheduled delivery options, visit the Tesamorelin wholesale pricing page. New wholesale accounts can apply through the wholesale program portal.
Quality Assurance, Testing, and COAs
Tesamorelin undergoes comprehensive analytical testing before lot release:
- HPLC — purity confirmation of 97% or greater with detailed chromatographic profiling to detect synthesis byproducts
- MALDI-TOF or ESI Mass Spectrometry — confirms the 5135.83 Da molecular weight and full 44-residue sequence integrity
- Peptide Content Determination — net peptide content quantification for accurate dosing in research protocols
- Endotoxin and Bioburden Testing — ensures suitability for in vivo and cell-based assay applications
Batch-specific Certificates of Analysis accompany every order. Access our COA library and review our testing methodology for detailed protocol information. See the Peptide COA Guide for help interpreting analytical reports.
Storage and Stability
Store Tesamorelin lyophilized powder at -20 degrees Celsius, protected from light and moisture. Under optimal conditions, the peptide remains stable for 18-24 months. Due to its larger size and multi-residue sequence, Tesamorelin is more susceptible to degradation than smaller peptides and temperature excursions should be minimized during shipping and storage. Once reconstituted in sterile water or appropriate buffer, use within 7-14 days when stored at 2-8 degrees Celsius. Aliquot reconstituted material to avoid repeated freeze-thaw cycles. For bulk powder shipments, cold-chain shipping with temperature monitoring is recommended.
Compliance and Intended Use
Tesamorelin is provided by Wholesale Bulk Peptides for research use only (RUO). It is not sold as a drug, dietary supplement, or food additive. While Tesamorelin has been the subject of advanced clinical investigation, the material supplied through our wholesale program is intended exclusively for qualified laboratory research. Purchasers must comply with all federal, state, and institutional regulations governing the acquisition and use of research peptides. Proper RUO labeling is required on all downstream packaging and distribution.
Related Compounds
Tesamorelin is frequently studied alongside other growth-hormone-axis peptides and metabolic research compounds:
- CJC-1295 — a GHRH analog with drug affinity complex (DAC) modification for extended half-life, enabling sustained GH elevation studies
- Ipamorelin — a selective GH secretagogue (ghrelin mimetic) studied for its clean GH release profile without cortisol or prolactin elevation
- Hexarelin — a potent GHSR agonist investigated for GH release and cardiovascular research applications
- AOD-9604 — an hGH fragment peptide studied for lipolytic activity without IGF-1 elevation
Browse the full Growth Factor / GH-IGF peptide catalog to design comprehensive secretagogue research programs. For entrepreneurs building peptide brands, see our Start a Peptide Brand resource.
Frequently Asked Questions About Tesamorelin
Our technical support team addresses common wholesale inquiries about Tesamorelin including reconstitution protocols, cold-chain shipping requirements, and analytical documentation. For product-specific FAQs, visit the Tesamorelin wholesale page. For program-level questions, see the wholesale peptides hub.
Disclaimer: This material is provided for informational and research purposes only. Tesamorelin is sold as a Research Use Only (RUO) compound. It is not intended for human or veterinary diagnostic or therapeutic use. All buyers are responsible for ensuring compliance with applicable laws and institutional guidelines. Wholesale Bulk Peptides makes no claims regarding the safety or efficacy of this compound for any purpose other than qualified laboratory research.